Related Experiment Video
Updated: Sep 13, 2026

Assessment of Maternal Vascular Remodeling During Pregnancy in the Mouse Uterus
Published on: December 5, 2015
Effect of gestational age on screening for neural-tube defects by maternal plasma-A.F.P. measurement
Maternal plasma or serum alpha-feto-protein (A.F.P.) concentrations were measured once between 8 and 22 weeks of gestation in each of sixty-two pregnancies which resulted in an infant with a neural-tube defect. Between 13 and 22 weeks of pregnancy twenty-two of the forty-one cases tested (54%) had A.F.P. values greater than three times the median value for unaffected pregnancies (which is equivalent to the 97th percentile of normal), and many of these values were very high indeed. However, before the 13th week of pregnancy only one of the twenty-one cases (5%) had an A.F.P. value more than three times the median for unaffected pregnancies, and this value was not very high. This indicates that in antenatal screening for anencephaly or spina bifida, A.F.P. should be measured in blood taken from the mother during the second trimester.
Maternal plasma or serum alpha-feto-protein (A.F.P.) concentrations were measured once between 8 and 22 weeks of gestation in each of sixty-two pregnancies which resulted in an infant with a neural-tube defect. Between 13 and 22 weeks of pregnancy twenty-two of the forty-one cases tested (54%) had A.F.P. values greater than three times the median value for unaffected pregnancies (which is equivalent to the 97th percentile of normal), and many of these values were very high indeed. However, before the 13th week of pregnancy only one of the twenty-one cases (5%) had an A.F.P. value more than three times the median for unaffected pregnancies, and this value was not very high. This indicates that in antenatal screening for anencephaly or spina bifida, A.F.P. should be measured in blood taken from the mother during the second trimester.

